AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Bioxcel Therapeutics shares rise 1.34% premarket after positive FDA comments on BXCL501 for agitation in bipolar disorder or schizophrenia.
ByAinvest
Friday, Aug 22, 2025 4:56 am ET1min read
Bioxcel Therapeutics, Inc. rose 1.34% in premarket trading, with the company announcing positive FDA comments from a pre-sNDA meeting for BXCL501 in agitation associated with bipolar disorder or schizophrenia. Additionally, the company reported a database lock in the SERENITY At-Home Phase-3 study for safety in acute agitation associated with bipolar disorder or schizophrenia.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet